Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BINTRAFUSP ALFA and Pimasertib for Intracranial Metastases
NCT04789668Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa, pimasertib in brain metastases, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2021; status: terminated.
02
Drugs
bintrafusp alfapimasertib
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT04789668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789668.